Otero Jose Manuel's Form 4 filing
Lexeo Therapeutics, Inc.LXEO · filed Nov 20, 2025
- Accession no.
- 0002024096-25-000005
- Filed
- Nov 20, 2025
- Trade date
- Aug 18, 2025
- Filing delay
- 94 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $6.68K. It was filed 94 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0002024096-26-000004 (Feb 20, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Otero Jose ManuelCIK 0002024096 | Officer (Chief Technical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | SSaleDisposed | −721 | $9.27F2 | −$6,683.67 | 63,476 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.